45. David Farber Discusses the Implications of CMS' Recent National Coverage Decision Proposal For FDA Approved Alzheimer's Treatments
Update: 2022-01-28
Description
On January 11th, the Centers for Medicare & Medicaid Services released an NCD proposal that would require “coverage with evidence development” for monoclonal antibody therapies aimed at amyloid for the treatment of Alzheimer’s disease. CMS’ coverage determination is deeply troubling, as it restricts Medicare recipient access to critical treatment.
Here today to discuss CMS’ national coverage determination and its implications on patients who suffer from Alzheimer’s Disease and other dementias is David Farber, an expert on international reference pricing, healthcare reimbursement, and the regulatory approval process for drugs and medical devices.
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
